Open Orphan PLC Early adopters signed for Genomic Health DataBANK
November 25 2019 - 2:01AM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
25 November 2019
25th November 2019
Open Orphan plc
("Open Orphan" or the "Company")
Early adopters signed for Genomic Health DataBANK
Open Orphan, a European-focussed, rare and orphan drug
consulting services platform, is pleased to announce it has signed
five pharmaceutical and biotechnology companies as early adopters
of its Genomic Health DataBANK platform. The platform is expected
to be completed and rolled out in Q1 2020.
The five companies signed up to the Genomic Health DataBANK
platform will ensure the database is 'fit-for-purpose' from a
pharmaceutical and data analysis perspective ahead of the first
patient data upload. This builds upon our previously announced
collaboration with Empiric Logic who will work with the Company to
complete the platform.
In conjunction, Open Orphan is working to finalise early adopter
agreements with several Patient Advocacy Groups, who will make
their patients aware of Open Orphan's Genomic Database. The Company
hopes to make an announcement on this front shortly.
These strategic agreements will allow Open Orphan to deliver on
its objective to build Europe's first rare disease, advocacy-led
genomic database which will empower patients to directly drive
research into their own respective disease.
Maurice Treacy, Chief Commercial Officer of Open Orphan
commented:
"We are very excited to be working with these leading
pharmaceutical and biotechnology companies on our market leading
DataBANK. The Genomic Health DataBANK, which makes extensive use of
AI tools, is an innovative research tool for pharmaceutical
companies, and we are excited by its potential when launched in
early 2020. We believe the DataBANK can ignite research for new
diagnostic tools and therapeutic products for rare disease
patients."
Enquiries:
Open Orphan plc Tel: +353 1 644 0007
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44
(0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1
679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Dan Sherwen
Notes to Editors on Open Orphan:
Open Orphan plc is a European-focused, rare and orphan drug
consulting services platform. The Company intends to roll up a
number of orphan drug services businesses. Open Orphan has two data
driven digital platforms, a Genomic Health Data Platform, which is
establishing a rare disease database and a Virtual Rep platform,
enabling pharmaceutical companies to engage key opinion leaders and
physicians. The Company is targeting rapid growth in one of the
fastest growing sectors in the global pharmaceutical industry
targeting under-supplied treatment for life threatening or very
serious diseases and rare disorders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABZLFLKFFFFBX
(END) Dow Jones Newswires
November 25, 2019 02:01 ET (07:01 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jul 2023 to Jul 2024